Harrier Inc. of Los Angeles (NASDAQ:HARE) said this week thatit had filed three patent applications on its glycosylationtechnology for pharmaceuticals, which it co-owns with theUniversity of Michigan.

"Compared to the Ferrier glycosylation process (the prior art inthis area), we use a different catalyst and a different reagent,"Harrier President Kevin DeVito said.

"You can't use the Ferrier process to glycosylate most of thedrugs we're looking at," he said, "because it's too harsh."

DeVito said compounds glycosylated with Harrier's process "canbe scaled up quite easily."

(c) 1997 American Health Consultants. All rights reserved.